Goldman Sachs gives three reasons against GRANOLAS stocks
- Investing.com
Pro- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Novo Nordisk A/S (NVO)
Novo Nordisk A/S stock price live, this page displays NYSE NVO stock exchange data. View the NVO premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Novo Nordisk A/S real time stock price chart below.
What Is the Novo Nordisk A/S Stock Price Today?
The Novo Nordisk A/S stock price today is 78.69.
What Is the Stock Symbol for Novo Nordisk A/S?
The stock symbol for Novo Nordisk A/S is "NVO."
What Stock Exchange Does Novo Nordisk A/S Trade On?
Novo Nordisk A/S is listed and trades on the NYSE stock exchange.
Is Novo Nordisk A/S a Good Stock to Buy?
Determining whether Novo Nordisk A/S—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NVO quote. (ISIN: US6701002056)
What Is the Novo Nordisk A/S Stock Price Today?
The Novo Nordisk A/S stock price today is 78.69.
What Is the Stock Symbol for Novo Nordisk A/S?
The stock symbol for Novo Nordisk A/S is "NVO."
What Stock Exchange Does Novo Nordisk A/S Trade On?
Novo Nordisk A/S is listed and trades on the NYSE stock exchange.
Is Novo Nordisk A/S a Good Stock to Buy?
Determining whether Novo Nordisk A/S—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NVO quote. (ISIN: US6701002056)
78.69
-4.38(-5.27%)
Closed
After Hours
78.91+0.22(+0.28%)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
78.17
80.88
52 wk Range
78.17
148.15
NVO Scorecard
Full Analysis
Has raised its dividend for 7 consecutive years
Unusual trading volume
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
78.1780.88
52 wk Range
78.17148.15
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(1.30%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(1.30%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
NVO Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceFair Price
Upside
Technical Analysis
Strong Sell
Price Target
110.96
Upside
+41.01%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
5 analysts have revised their earnings downwards for the upcoming period
- Novo Nordisk receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Goldman Sachs gives three reasons against GRANOLAS stocks
- Investing.com
Pro - Novo Nordisk receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Novo Nordisk A/S Company Profile
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases; and with Valo Health, Inc. to discover and develop novel treatments for obesity, type 2 diabetes, and cardiovascular disease. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Novo Nordisk A/S SWOT Analysis
Obesity Drug Dominance | Novo Nordisk leads the obesity treatment market with groundbreaking GLP-1 therapies, driving substantial revenue growth and market expansion |
Manufacturing Mastery | Explore Novo Nordisk's $4.1 billion investment in manufacturing capacity, aiming to address supply constraints and create a competitive moat |
Pipeline Potential | Delve into Novo Nordisk's innovative pipeline, featuring promising candidates like Amycretin and CagriSema, poised to drive future growth |
Analyst Optimism | Analysts maintain bullish outlook with price targets ranging from $160 to $163, reflecting confidence in Novo Nordisk's market position and growth prospects |
Novo Nordisk A/S Earnings Call Summary for Q3/2024
- Q3 2024: Sales up 24%, operating profit up 22%; GLP-1 treatments reach 43M+ patients; carbon emissions rise 34% due to higher capex
- North America ops grow 31%, international 15%; Wegovy sales surge 77% globally; U.S. weekly prescriptions near 215,000
- 2024 guidance: Sales growth 23-27%, operating profit growth 21-27%; Capex forecast at DKK 45B for production expansion
- R&D advancements: Positive trial results for oral semaglutide; regulatory filings expected early 2025
- Catalent acquisition to close end-2024; 2025 sales growth projected in high teens; strong market share in GLP-1 treatments anticipated
Last Updated: 07/11/2024, 08:14 am
Read Full TranscriptCompare NVO to Peers and Sector
Metrics to compare | NVO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNVOPeersSector | |
|---|---|---|---|---|
P/E Ratio | 27.0x | 15.3x | −0.6x | |
PEG Ratio | 1.01 | 0.12 | 0.00 | |
Price/Book | 21.2x | 4.5x | 2.6x | |
Price / LTM Sales | 9.4x | 3.5x | 3.1x | |
Upside (Analyst Target) | 31.6% | 10.7% | 53.6% | |
Fair Value Upside | Unlock | 14.8% | 8.0% | Unlock |
Analyst Ratings
6 Buy
3 Hold
1 Sell
Ratings:
10 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 110.96
(+41.01% Upside)
Earnings
Latest Release
Nov 06, 2024
EPS / Forecast
6.12 / 0.8813
Revenue / Forecast
71.31B / 10.60B
People Also Watch
FAQ
What Is the Novo Nordisk ADR (NVO) Stock Price Today?
The Novo Nordisk ADR stock price today is 78.69
What Stock Exchange Does Novo Nordisk ADR Trade On?
Novo Nordisk ADR is listed and trades on the NYSE stock exchange.
What Is the Stock Symbol for Novo Nordisk ADR?
The stock symbol for Novo Nordisk ADR is "NVO."
Does Novo Nordisk ADR Pay Dividends? What’s The Current Dividend Yield?
The Novo Nordisk ADR dividend yield is 1.30%.
What Is the Novo Nordisk ADR Market Cap?
As of today, Novo Nordisk ADR market cap is 351.97B.
What is Novo Nordisk ADR Earnings Per Share?
The Novo Nordisk ADR EPS is 21.25.
What Is the Next Novo Nordisk ADR Earnings Date?
Novo Nordisk ADR will release its next earnings report on 04 Feb 2025.
From a Technical Analysis Perspective, Is NVO a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.